No Data
List of stocks with cleared skies (weekly chart) (Part 1)
○ List of Breakthrough Stocks in the Market Code Stock Name Closing Price Leading Span A Leading Span B Tokyo Stock Exchange main board <1332> Nissui 938 903.25 809 <1786> Oriental Shiraishi 3783.75 348.5 <1888> Wakachiku Ken 3565 3458.75 3463 <1939> Shidenko 1360 1219.5 1046 <2124> JACR 732 728.25 679
List of Conversion Stocks (Part 1) [List of Parabolic Signal Conversion Stocks]
○ List of buy conversion stocks in the market Code Stock name Closing price SAR Tokyo main board <3198> SFP 1913 1873 <4902> Konica Minolta 5334 72 <6369> Toyokanetsu 4350 42 80 <6875> Megachips 5490 52 30 <6995> Tokai Riden 1976 1935 <7259> Aisin 1642 1551 <7270> Subaru 2665 2503 <7
List of Cloud Breakout Stocks [Ichimoku Balance Table, List of Cloud Breakout Stocks]
List of breakout stocks above the cloud in the market Code Stock name Closing price Leading Span A Leading Span B Tokyo Stock Exchange Prime Board <1515> Nittetsu Kogyo 4475 4316.25 4455 <1888> Wakuzuku Kensetsu363035033391 <2915> Kenko Mayo234522582134.5 <3073> DD Group12811276.51225 <3923> Laxus22312188.52000.
Stocks that moved the previous day part1 include Shochiku, AeroEdge, Koshidaka HD, etc.
Stock name <Code> 11th closing price ⇒ Previous day comparison Shochiku <9601> 9246 -106925 Financial estimates for the fiscal year ending February 25 have been revised downward. Vitz <4440> 840 +30 Operating profit is expected to increase by 50.6% in the previous period and 19.6% in this period. Part-time Thai <2341> 143 -8 The operating profit for the first half decreased by 98.2%, expanding the decrease rate from 80.3% in the first quarter. Chordia <190A> 296 -38 At the Japan Society of Hematology Academic Meeting, the first-phase clinical trial of the CLK inhibitor CTX-712.
Active and newly established stocks in the afternoon session.
*Matsushita <9601> 9246 -106 Lowered financial estimates for the fiscal year ending February 2025. *Vitz <4440> 840 +30 Operating profit expected to increase by 50.6% from the previous period and by 19.6% for the current period. *Albaitai <2341> 143 -8 The operating profit for the first half decreased by 98.2%, expanding the decrease rate from 80.3% in the first quarter. *Chordia <190A> 296 -38 Announcement of the results of the Phase I clinical trial of the CLK inhibitor CTX-712 at the Japan Society of Hematology Annual Meeting. *Aer
Shochiku: Confirmation letter
No Data